Determining Patients And Doctors Preferences For Chemotherapy And Incorporating Them Into Clinical Decision-making
Funder
National Health and Medical Research Council
Funding Amount
$87,234.00
Summary
Chemotherapy improves survival in early lung cancer and advanced ovarian cancer but has significant side effects. Recent advances in chemotherapy have not been widely adopted because of differing opinions about whether the benefits of these treatments outweigh their harms. This research program will determine the benefits that patients and their doctors judge necessary to make these treatments worthwhile, and how best to incorporate this information into clinical discussions and decision-making.
Defining Steps In The Molecular Pathogenesis Of Lung Cancer Using Immortalized Human Bronchial Epithelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$374,344.00
Summary
Lung cancer remains the leading cause of cancer death worldwide and is caused by abnormalities in DNA. This project aims to further our understanding of this disease by altering known cancer-related genes and studying their effect on lung cancer development. This project also aims to identify novel genes in lung cancer as well as tumour expression profiles which can predict response to chemotherapy agents. In summary, this research will identify new gene targets for therapeutic agents.
An Exploration Of Functional Decline And The Potential For Rehab In Patients With Advanced Non-small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$50,000.00
Summary
Lung cancer is one of the commonest human cancers and the leading cause of cancer deaths. People with advanced cancer experience significant decline in functional capacity as their disease advances and they approach death. This decline is likely to have significant impact on quality of life. In lung cancer this decline can be exacerbated by chronic illnesses such as chronic obstructive pulmonary disease (COPD). While significant clinical benefits have been demonstrated in COPD patients with the ....Lung cancer is one of the commonest human cancers and the leading cause of cancer deaths. People with advanced cancer experience significant decline in functional capacity as their disease advances and they approach death. This decline is likely to have significant impact on quality of life. In lung cancer this decline can be exacerbated by chronic illnesses such as chronic obstructive pulmonary disease (COPD). While significant clinical benefits have been demonstrated in COPD patients with the introduction of pulmonary rehabilitation, little research has been conducted to either map the functional status of lung cancer patients or to explore the application of pulmonary rehabilitation in this setting. This study seeks to begin a program of work in this area through first exploring the characteristics of functional decline in this group and then assessing the feasibility and acceptability of a rehabilitation program specifically addressing the functional status needs identified.Read moreRead less
Interactions Between Hedgehog And Ras Signaling In Lung Adenocarcinoma
Funder
National Health and Medical Research Council
Funding Amount
$295,983.00
Summary
Lung cancer is a common and lethal disease in our community. In this project, we explore how signaling pathways that regulate the development of the lung in embryos contribute to the initation and progression of lung cancer. To do this, we use a mouse model of lung cancer in which we can activate embryonic signaling pathways in adult mice to study there effect on the disease. Understanding these pathways will help us to better treat and prevent lung cancer in humans.
Improving Cancer Therapy: Nanoparticle Delivery Of SiRNA To Cancer Cells
Funder
National Health and Medical Research Council
Funding Amount
$610,499.00
Summary
Lung cancer accounts for 8000 diagnosis and 1000 deaths in Australia each year. We are using cutting edge nanotechnology and coupling this with potent gene silencing to target solid tumours of the lung. If successful, this approach could increase survival of patients with this difficult to treat malignancy and may prove valuable in the treatment of other lung tumours.
An In-vivo Model Of Acquired Chemoresistance In Small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$363,827.00
Summary
Lung cancer is a common and lethal disease in our community. In this project, we explore how a very aggressive form of lung cancer becomes resistant to chemotherapy. To do this, we use a new mouse model of lung cancer in which we can study how human lung cancer cells develop resistance to chemotherapy in vivo. Understanding these pathways will help us to better treat lung cancer with chemotherapy.
Identifying The Targets Of MiRNA Regulation In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$290,600.00
Summary
microRNAs are noncoding RNAs with fundamental functions in biology and significant roles disease. microRNAs control gene expression by destroying RNA or controlling its translation into cellular proteins. To determine how certain microRNAs cause human disease it is essential to know their RNA targets. We are developing methods to identify these targets and aim to apply these methods to identify the targets of microRNAs with known roles in cancer.
Optimising Regulatory T Cell Depletion In Combination With Chemotherapy For Enhanced Anti-tumour Immunity
Funder
National Health and Medical Research Council
Funding Amount
$264,816.00
Summary
The drug cyclophosphamide helps the immune system attack cancer by decreasing the number of immune cells that suppress an immune response to cancer ('Regulatory T cells'). This project combines standard chemotherapy with the drug cyclophosphamide in people with mesothelioma and lung cancer. The aim of the project is to find the dose of cyclophosphamide that maximally decreases Regulatory T cells in each patient, and determine the effect of this on anti-tumour immunity and response to treatment.